Official ESCRS | European Society of Cataract & Refractive Surgeons
London 2014 Registration Visa Letters Programme Satellite Meetings Glaucoma Day 2014 Exhibition Hotel Booking Virtual Exhibition Star Alliance
london escrs

Course handouts are now available
Click here

Come to London


WATCH to find out why

Site updates:

Programme Updates. Programme Overview and - Video Symposium on Challenging Cases now available.


Search Abstracts by author or title
(results will display both Free Papers & Poster)

Toric AT TORBI 709M/MP (Carl Zeiss) intraocular lens implantation (IOL) in cataract patients with moderate and high corneal astigmatism

Poster Details

First Author: D.Dementiev RUSSIA

Co Author(s):    A. Shipunova   M. Sysoeva           

Abstract Details


To evaluate refractive outcomes, rotational stability and safety of lens exchange with customized AT TORBI 709M/MP (Carl Zeiss) IOL to correct high and moderate regular corneal astigmatism in cataract patients.


“Blue Eye” Centro di Chirurgia Oculare, Milano, Italy, “International Center for Ophthalmology”, Moscow, Russia


Phacoemulsification cataract extraction and implantation of an AT Torbi 709M IOL were performed. The uncorrected (UDVA) and corrected (CDVA) distance visual acuities, corneal cylinder, refraction, and IOL axis were evaluated preoperatively and postoperatively up to 26 months.


The study enrolled 16 eyes of 10 patients with a mean age of 56 years ± 8,4 (SD). The mean refractive spherical equivalent decreased significantly, from -2.53 ± 3.62 D to -0.41 ± 0.71 D 1 day postoperatively (P.001). The mean refractive astigmatism decreased, from -4.29 ± 1.62 D to -1.01 ± 0.54 D (P<.001). There was a significant improvement in the mean UDVA (from 0.82 ± 0.47 log MAR to 0.15 ± 0.12 log MAR), in the mean CDVA (from 0.26 ± 0.16 log MAR to 0.04 ± 0.11 log MAR both P<.001).


Lens exchange for customized toric AT TORBI 709M/MP (Carl Zeiss) IOL is rotationally stable and shows excellent capsule bag performance and refractive outcomes.

Financial Disclosure:

One or more of the authors receives non-monetary benefits from a company producing, developing or supplying the product or procedure presented.

Back to Poster listing